$RSLS
ReShape Lifesciences Inc.

2016 Q4 Form 10-Q Financial Statement

#000156459016028928 Filed on November 10, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q3
Revenue $772.0K $773.0K $1.093M
YoY Change -21.46% -29.28%
Cost Of Revenue $90.00K $644.0K $644.0K
YoY Change 28.57% 0.0%
Gross Profit -$99.00K $129.0K $449.0K
YoY Change -130.09% -71.27%
Gross Profit Margin -12.82% 16.69% 41.08%
Selling, General & Admin $2.890M $2.412M $618.0K
YoY Change -51.35% 290.29% -81.22%
% of Gross Profit 1869.77% 137.64%
Research & Development $1.290M $2.169M $3.201M
YoY Change -23.67% -32.24% 38.57%
% of Gross Profit 1681.4% 712.92%
Depreciation & Amortization $30.00K $30.00K $50.00K
YoY Change -25.0% -40.0% 0.0%
% of Gross Profit 23.26% 11.14%
Operating Expenses $4.180M $4.581M $3.819M
YoY Change -45.22% 19.95% -31.68%
Operating Profit -$7.534M -$4.452M -$3.370M
YoY Change 61.19% 32.11% -39.71%
Interest Expense -$530.0K -$135.0K -$142.0K
YoY Change -167.95% -4.93% 18.33%
% of Operating Profit
Other Income/Expense, Net $220.0K -$4.000K -$8.000K
YoY Change -50.0%
Pretax Income -$4.430M -$6.520M -$4.150M
YoY Change -34.56% 57.11% -27.32%
Income Tax
% Of Pretax Income
Net Earnings -$7.495M -$5.260M -$3.562M
YoY Change 54.92% 47.67% -37.62%
Net Earnings / Revenue -970.85% -680.47% -325.89%
Basic Earnings Per Share
Diluted Earnings Per Share -$670.0B -$2968B -$10570B
COMMON SHARES
Basic Shares Outstanding 16.77M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.310M $6.840M $12.26M
YoY Change -58.26% -44.21% -24.65%
Cash & Equivalents $72.98M $2.324M $1.670M
Short-Term Investments $2.500M $11.80M
Other Short-Term Assets $1.244M $2.857M $230.0K
YoY Change 355.68% 1142.17% -4.17%
Inventory $827.0K $438.0K $1.380M
Prepaid Expenses $962.0K $353.0K
Receivables $0.00 $190.0K $30.00K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $78.06M $17.96M $13.89M
YoY Change 465.54% 29.32% -20.31%
LONG-TERM ASSETS
Property, Plant & Equipment $717.0K $535.0K $370.0K
YoY Change 71.53% 44.59% -19.57%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.120M $810.0K $750.0K
YoY Change 47.37% 8.0% -25.0%
Total Long-Term Assets $717.0K $535.0K $1.120M
YoY Change 71.53% -52.23% -23.29%
TOTAL ASSETS
Total Short-Term Assets $78.06M $17.96M $13.89M
Total Long-Term Assets $717.0K $535.0K $1.120M
Total Assets $78.78M $18.50M $15.01M
YoY Change 453.96% 23.24% -20.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $595.0K $680.0K $200.0K
YoY Change 250.0% 240.0% 300.0%
Accrued Expenses $2.750M $2.850M $3.480M
YoY Change -23.61% -18.1% -21.09%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $4.440M $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $4.592M $5.207M $3.680M
YoY Change -17.51% 41.49% -56.29%
LONG-TERM LIABILITIES
Long-Term Debt $9.881M $9.886M $0.00
YoY Change 8.65%
Other Long-Term Liabilities $40.00K $210.0K $3.590M
YoY Change -98.61% -94.15%
Total Long-Term Liabilities $9.881M $9.886M $3.590M
YoY Change 8.65% 175.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.592M $5.207M $3.680M
Total Long-Term Liabilities $9.881M $9.886M $3.590M
Total Liabilities $14.47M $15.09M $7.270M
YoY Change -1.28% 107.61% -13.66%
SHAREHOLDERS EQUITY
Retained Earnings -$76.61M -$69.11M
YoY Change 36.46%
Common Stock $140.9M $2.016M
YoY Change 13949.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $64.31M -$67.09M $7.740M
YoY Change
Total Liabilities & Shareholders Equity $78.78M $18.50M $15.01M
YoY Change 453.96% 23.24% -20.54%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$7.495M -$5.260M -$3.562M
YoY Change 54.92% 47.67% -37.62%
Depreciation, Depletion And Amortization $30.00K $30.00K $50.00K
YoY Change -25.0% -40.0% 0.0%
Cash From Operating Activities -$3.540M -$4.630M -$6.030M
YoY Change -34.08% -23.22% 37.67%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $9.300M $2.080M $3.450M
YoY Change 56.04% -39.71%
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -40.00K 13.50M
YoY Change -100.0% -100.3% -1450.0%
NET CHANGE
Cash From Operating Activities -3.540M -4.630M -6.030M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 0.000 -40.00K 13.50M
Net Change In Cash -3.540M -4.670M 7.470M
YoY Change -18.43% -162.52% -238.33%
FREE CASH FLOW
Cash From Operating Activities -$3.540M -$4.630M -$6.030M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow -$3.540M -$4.630M -$6.030M
YoY Change -34.08% -23.22% 38.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2016-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Trading Symbol
TradingSymbol
OBLN
dei Entity Registrant Name
EntityRegistrantName
OBALON THERAPEUTICS INC
dei Entity Central Index Key
EntityCentralIndexKey
0001427570
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16772818
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2324000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3356000
CY2016Q3 us-gaap Short Term Investments
ShortTermInvestments
11829000
CY2015Q4 us-gaap Short Term Investments
ShortTermInvestments
9175000
CY2016Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
515000
CY2015Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
636000
CY2016Q3 us-gaap Inventory Net
InventoryNet
438000
CY2015Q4 us-gaap Inventory Net
InventoryNet
363000
CY2016Q3 us-gaap Other Assets Current
OtherAssetsCurrent
2857000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
273000
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-69114000
CY2016Q3 us-gaap Assets Current
AssetsCurrent
17963000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
13803000
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
535000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
418000
CY2016Q3 us-gaap Assets
Assets
18498000
CY2015Q4 us-gaap Assets
Assets
14221000
CY2016Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1068000
CY2015Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
549000
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
684000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1250000
CY2016Q3 obln Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
139000
CY2015Q4 obln Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
913000
CY2016Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2434000
CY2015Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
493000
CY2015Q4 us-gaap Related Party Deposit Liabilities
RelatedPartyDepositLiabilities
1283000
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
747000
CY2016Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
882000
CY2015Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
332000
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5207000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5567000
CY2016Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9886000
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
9094000
CY2016Q3 us-gaap Liabilities
Liabilities
15093000
CY2015Q4 us-gaap Liabilities
Liabilities
14661000
CY2016Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
70498000
CY2015Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
54699000
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2015000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1002000
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56142000
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
-67093000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-55139000
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18498000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14221000
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45000000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1383624
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
575126
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1383624
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
575126
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
224000
CY2016Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
773000
CY2015Q3 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
1093000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
2621000
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
2832000
CY2016Q3 us-gaap Revenues
Revenues
773000
CY2015Q3 us-gaap Revenues
Revenues
1093000
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
574044
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
706688
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-405000
CY2016Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
669000
us-gaap Revenues
Revenues
2621000
us-gaap Revenues
Revenues
3056000
CY2016Q3 us-gaap Cost Of Revenue
CostOfRevenue
644000
CY2015Q3 us-gaap Cost Of Revenue
CostOfRevenue
644000
us-gaap Cost Of Revenue
CostOfRevenue
1938000
us-gaap Cost Of Revenue
CostOfRevenue
1849000
CY2016Q3 us-gaap Gross Profit
GrossProfit
129000
CY2015Q3 us-gaap Gross Profit
GrossProfit
449000
us-gaap Gross Profit
GrossProfit
683000
us-gaap Gross Profit
GrossProfit
1207000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2169000
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3201000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7267000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9169000
CY2016Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2412000
CY2015Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
618000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5387000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2297000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
4581000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
3819000
us-gaap Operating Expenses
OperatingExpenses
12654000
us-gaap Operating Expenses
OperatingExpenses
11466000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4452000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3370000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11971000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10259000
CY2016Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-135000
CY2015Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-142000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-425000
CY2015Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
42000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
550000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
31000
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4000
CY2015Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-26000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-24000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-5260000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-3562000
us-gaap Net Income Loss
NetIncomeLoss
-12972000
us-gaap Net Income Loss
NetIncomeLoss
-10719000
CY2016Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1000
CY2015Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
8000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5259000
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3564000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12967000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10711000
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.46
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.21
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-18.36
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-18.71
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
963724
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
572818
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-96000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-215000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1032000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
142000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5232000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
124000
us-gaap Share Based Compensation
ShareBasedCompensation
200000
us-gaap Share Based Compensation
ShareBasedCompensation
153000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-13000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
2597000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
60000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
57000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-97000
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-121000
us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
542000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
75000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-103000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
39000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
5000000
us-gaap Payments Of Debt Restructuring Costs
PaymentsOfDebtRestructuringCosts
15000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1065000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
61000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
15567000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5061000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
3000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
519000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
268000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-566000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-33000
obln Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
-774000
obln Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
1623000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1690000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
202000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
1283000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13593000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7175000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
18897000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
14238000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
16150000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
11200000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
259000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
83000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3006000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-3121000
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
14517000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6902000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1670000
us-gaap Interest Paid
InterestPaid
405000
us-gaap Interest Paid
InterestPaid
371000
obln Conversion Of Customer Deposit From Related Party To Preferred Stock
ConversionOfCustomerDepositFromRelatedPartyToPreferredStock
1283000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with Generally Accepted Accounting Principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the warrant liability, stock-based compensation, and income tax uncertainties.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reported amounts and note disclosures reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ materially from those estimates. All revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p></div>
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
242000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
2.9-to-1 ratio
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.3448
CY2015Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2016Q3 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
13878000
CY2016Q3 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
882000
CY2015Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
12768000
CY2015Q4 us-gaap Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
332000
CY2016Q3 obln Fair Value Assets And Liabilities Transfers Between Levels Amount
FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount
0
CY2015Q4 obln Fair Value Assets And Liabilities Transfers Between Levels Amount
FairValueAssetsAndLiabilitiesTransfersBetweenLevelsAmount
0
CY2014Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
56000
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
34000
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
332000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
550000
CY2016Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
882000
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10524386
CY2015Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8443994
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9745510
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8443994
CY2016Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
315000
CY2015Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
235000
CY2016Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
12000
CY2015Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
121000
CY2016Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
111000
CY2015Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7000
CY2016Q3 us-gaap Deferred Costs Current
DeferredCostsCurrent
2363000
CY2016Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
353000
CY2015Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
234000
CY2016Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
52000
CY2015Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
25000
CY2016Q3 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
89000
CY2015Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
14000
CY2016Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1569000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1312000
CY2016Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1034000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
894000
CY2016Q3 obln Accrued Ipo Costs Current
AccruedIPOCostsCurrent
993000
CY2016Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
677000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
195000
CY2016Q3 obln Accrued Legal Current
AccruedLegalCurrent
257000
CY2015Q4 obln Accrued Legal Current
AccruedLegalCurrent
162000
CY2016Q3 us-gaap Interest Payable Current
InterestPayableCurrent
38000
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
44000
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
469000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
92000
CY2016Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10000000
CY2016Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
114000
CY2016Q3 us-gaap Long Term Debt
LongTermDebt
9886000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0142
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0157
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0157
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5296
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6153
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6153
CY2016Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2015Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2015Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2016Q3 us-gaap Share Based Compensation
ShareBasedCompensation
55000
CY2015Q3 us-gaap Share Based Compensation
ShareBasedCompensation
53000
CY2016Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y3M18D
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1298868
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
740782
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
808498
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
41904
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1189248
CY2016Q2 obln Temporary Equity Conversion Price Per Share
TemporaryEquityConversionPricePerShare
12.44
CY2016Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11858374
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1098691
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
397373
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.44
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.85
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.32
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.23
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.74
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.75
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
1.76
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y3M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15503000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
14298000
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
4998000
obln Stock Options Early Exercised
StockOptionsEarlyExercised
252453
CY2016Q3 obln Nonvested Stock Options Early Exercised
NonvestedStockOptionsEarlyExercised
246927
CY2016Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
34460759
CY2016Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
10096639
CY2016Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
10096639
CY2016Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
71506000
CY2016Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
85336
CY2016Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
7.4408
CY2016Q2 obln Minimum Percentage Of Voting Required For Conversion Of Temporary Equity To Common Stock
MinimumPercentageOfVotingRequiredForConversionOfTemporaryEquityToCommonStock
0.67
CY2016Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
63805954
CY2016Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
79460759
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
45000000
CY2016Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
34460759
CY2016Q2 obln Temporary Equity Conversion Price Per Share
TemporaryEquityConversionPricePerShare
11.3025
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2017-03-31
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
71000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
71000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
142000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
200000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
200000

Files In Submission

Name View Source Status
0001564590-16-028928-index-headers.html Edgar Link pending
0001564590-16-028928-index.html Edgar Link pending
0001564590-16-028928.txt Edgar Link pending
0001564590-16-028928-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
obln-10q_20160930.htm Edgar Link pending
obln-20160930.xml Edgar Link completed
obln-20160930.xsd Edgar Link pending
obln-20160930_cal.xml Edgar Link unprocessable
obln-20160930_def.xml Edgar Link unprocessable
obln-20160930_lab.xml Edgar Link unprocessable
obln-20160930_pre.xml Edgar Link unprocessable
obln-ex106_175.htm Edgar Link pending
obln-ex107_176.htm Edgar Link pending
obln-ex311_177.htm Edgar Link pending
obln-ex312_178.htm Edgar Link pending
obln-ex321_174.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending